Pre-Study protocol MagPEP

A multicentre randomized controlled trial of magnesium sulphate in the prevention of post-ERCP pancreatitis

Gabriele Fluhr, Julia Mayerle, Eckhard Weber, Ali Aghdassi, Peter Simon, Thomas Gress, Thomas Seufferlein, Joachim Mössner, Andreas Stallmach, Thomas Rösch, Martina Müller, Britta Siegmund, Petra Büchner-Steudel, Ina Zuber-Jerger, Marcus Kantowski, Albrecht Hoffmeister, Jonas Rosendahl, Thomas Linhart, Jochen Maul, L. Czakó & 10 others P. Hegyi, Matthias Kraft, Georg Engel, Thomas Kohlmann, Anne Glitsch, Tilman Pickartz, Christoph Budde, Claudia Nitsche, Kirsten Storck, Markus M. Lerch

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Acute pancreatitis is the most common complication of diagnostic and therapeutic endoscopic retrograde cholangiopancreatography (ERCP). In spite of continuing research, no pharmacologic agent capable of effectively reducing the incidence of ERCP-induced pancreatitis has found its way into clinical practise. A number of experimental studies suggest that intrapancreatic calcium concentrations play an important role in the initiation of intracellular protease activation, an initiating step in the course of acute pancreatitis. Magnesium can act as a calcium-antagonist and counteracts effects in calcium signalling. It can thereby attenuate the intracellular activation of proteolytic digestive enzymes in the pancreas and reduces the severity of experimental pancreatitis when administered either intravenously or as a food supplement. Methods: We designed a randomized, double-blind, placebo-controlled phase III study to test whether the administration of intravenous magnesium sulphate before and after ERCP reduces the incidence and the severity of post-ERCP pancreatitis. A total of 502 adult patients with a medical indication for ERCP are to be randomized to receive either 4930 mg magnesium sulphate (= 20 mmol magnesium) or placebo 60 min before and 6 hours after ERCP. The incidence of clinical post-ERCP pancreatitis, hyperlipasemia, pain levels, use of analgetics and length of hospital stay will be evaluated. Conclusions: If magnesium sulphate is found to be effective in preventing post-ERCP pancreatitis, this inexpensive agent with limited adverse effects could be used as a routine pharmacological prophylaxis.Trial registration: Current Controlled Trials ISRCTN46556454.

Original languageEnglish
Pages (from-to)11
Number of pages1
JournalBMC Gastroenterology
DOIs
Publication statusAccepted/In press - Jan 15 2013

Fingerprint

Magnesium Sulfate
Endoscopic Retrograde Cholangiopancreatography
Pancreatitis
Randomized Controlled Trials
Magnesium
Length of Stay
Incidence
Peptide Hydrolases
Placebos
Calcium
Calcium Signaling
Dietary Supplements
Intravenous Administration
Pancreas
Pharmacology
Pain

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Pre-Study protocol MagPEP : A multicentre randomized controlled trial of magnesium sulphate in the prevention of post-ERCP pancreatitis. / Fluhr, Gabriele; Mayerle, Julia; Weber, Eckhard; Aghdassi, Ali; Simon, Peter; Gress, Thomas; Seufferlein, Thomas; Mössner, Joachim; Stallmach, Andreas; Rösch, Thomas; Müller, Martina; Siegmund, Britta; Büchner-Steudel, Petra; Zuber-Jerger, Ina; Kantowski, Marcus; Hoffmeister, Albrecht; Rosendahl, Jonas; Linhart, Thomas; Maul, Jochen; Czakó, L.; Hegyi, P.; Kraft, Matthias; Engel, Georg; Kohlmann, Thomas; Glitsch, Anne; Pickartz, Tilman; Budde, Christoph; Nitsche, Claudia; Storck, Kirsten; Lerch, Markus M.

In: BMC Gastroenterology, 15.01.2013, p. 11.

Research output: Contribution to journalArticle

Fluhr, G, Mayerle, J, Weber, E, Aghdassi, A, Simon, P, Gress, T, Seufferlein, T, Mössner, J, Stallmach, A, Rösch, T, Müller, M, Siegmund, B, Büchner-Steudel, P, Zuber-Jerger, I, Kantowski, M, Hoffmeister, A, Rosendahl, J, Linhart, T, Maul, J, Czakó, L, Hegyi, P, Kraft, M, Engel, G, Kohlmann, T, Glitsch, A, Pickartz, T, Budde, C, Nitsche, C, Storck, K & Lerch, MM 2013, 'Pre-Study protocol MagPEP: A multicentre randomized controlled trial of magnesium sulphate in the prevention of post-ERCP pancreatitis', BMC Gastroenterology, pp. 11. https://doi.org/10.1186/1471-230X-13-11
Fluhr, Gabriele ; Mayerle, Julia ; Weber, Eckhard ; Aghdassi, Ali ; Simon, Peter ; Gress, Thomas ; Seufferlein, Thomas ; Mössner, Joachim ; Stallmach, Andreas ; Rösch, Thomas ; Müller, Martina ; Siegmund, Britta ; Büchner-Steudel, Petra ; Zuber-Jerger, Ina ; Kantowski, Marcus ; Hoffmeister, Albrecht ; Rosendahl, Jonas ; Linhart, Thomas ; Maul, Jochen ; Czakó, L. ; Hegyi, P. ; Kraft, Matthias ; Engel, Georg ; Kohlmann, Thomas ; Glitsch, Anne ; Pickartz, Tilman ; Budde, Christoph ; Nitsche, Claudia ; Storck, Kirsten ; Lerch, Markus M. / Pre-Study protocol MagPEP : A multicentre randomized controlled trial of magnesium sulphate in the prevention of post-ERCP pancreatitis. In: BMC Gastroenterology. 2013 ; pp. 11.
@article{5ea0e619b4aa4075a0db7dbc762258a9,
title = "Pre-Study protocol MagPEP: A multicentre randomized controlled trial of magnesium sulphate in the prevention of post-ERCP pancreatitis",
abstract = "Background: Acute pancreatitis is the most common complication of diagnostic and therapeutic endoscopic retrograde cholangiopancreatography (ERCP). In spite of continuing research, no pharmacologic agent capable of effectively reducing the incidence of ERCP-induced pancreatitis has found its way into clinical practise. A number of experimental studies suggest that intrapancreatic calcium concentrations play an important role in the initiation of intracellular protease activation, an initiating step in the course of acute pancreatitis. Magnesium can act as a calcium-antagonist and counteracts effects in calcium signalling. It can thereby attenuate the intracellular activation of proteolytic digestive enzymes in the pancreas and reduces the severity of experimental pancreatitis when administered either intravenously or as a food supplement. Methods: We designed a randomized, double-blind, placebo-controlled phase III study to test whether the administration of intravenous magnesium sulphate before and after ERCP reduces the incidence and the severity of post-ERCP pancreatitis. A total of 502 adult patients with a medical indication for ERCP are to be randomized to receive either 4930 mg magnesium sulphate (= 20 mmol magnesium) or placebo 60 min before and 6 hours after ERCP. The incidence of clinical post-ERCP pancreatitis, hyperlipasemia, pain levels, use of analgetics and length of hospital stay will be evaluated. Conclusions: If magnesium sulphate is found to be effective in preventing post-ERCP pancreatitis, this inexpensive agent with limited adverse effects could be used as a routine pharmacological prophylaxis.Trial registration: Current Controlled Trials ISRCTN46556454.",
author = "Gabriele Fluhr and Julia Mayerle and Eckhard Weber and Ali Aghdassi and Peter Simon and Thomas Gress and Thomas Seufferlein and Joachim M{\"o}ssner and Andreas Stallmach and Thomas R{\"o}sch and Martina M{\"u}ller and Britta Siegmund and Petra B{\"u}chner-Steudel and Ina Zuber-Jerger and Marcus Kantowski and Albrecht Hoffmeister and Jonas Rosendahl and Thomas Linhart and Jochen Maul and L. Czak{\'o} and P. Hegyi and Matthias Kraft and Georg Engel and Thomas Kohlmann and Anne Glitsch and Tilman Pickartz and Christoph Budde and Claudia Nitsche and Kirsten Storck and Lerch, {Markus M.}",
year = "2013",
month = "1",
day = "15",
doi = "10.1186/1471-230X-13-11",
language = "English",
pages = "11",
journal = "BMC Gastroenterology",
issn = "1471-230X",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Pre-Study protocol MagPEP

T2 - A multicentre randomized controlled trial of magnesium sulphate in the prevention of post-ERCP pancreatitis

AU - Fluhr, Gabriele

AU - Mayerle, Julia

AU - Weber, Eckhard

AU - Aghdassi, Ali

AU - Simon, Peter

AU - Gress, Thomas

AU - Seufferlein, Thomas

AU - Mössner, Joachim

AU - Stallmach, Andreas

AU - Rösch, Thomas

AU - Müller, Martina

AU - Siegmund, Britta

AU - Büchner-Steudel, Petra

AU - Zuber-Jerger, Ina

AU - Kantowski, Marcus

AU - Hoffmeister, Albrecht

AU - Rosendahl, Jonas

AU - Linhart, Thomas

AU - Maul, Jochen

AU - Czakó, L.

AU - Hegyi, P.

AU - Kraft, Matthias

AU - Engel, Georg

AU - Kohlmann, Thomas

AU - Glitsch, Anne

AU - Pickartz, Tilman

AU - Budde, Christoph

AU - Nitsche, Claudia

AU - Storck, Kirsten

AU - Lerch, Markus M.

PY - 2013/1/15

Y1 - 2013/1/15

N2 - Background: Acute pancreatitis is the most common complication of diagnostic and therapeutic endoscopic retrograde cholangiopancreatography (ERCP). In spite of continuing research, no pharmacologic agent capable of effectively reducing the incidence of ERCP-induced pancreatitis has found its way into clinical practise. A number of experimental studies suggest that intrapancreatic calcium concentrations play an important role in the initiation of intracellular protease activation, an initiating step in the course of acute pancreatitis. Magnesium can act as a calcium-antagonist and counteracts effects in calcium signalling. It can thereby attenuate the intracellular activation of proteolytic digestive enzymes in the pancreas and reduces the severity of experimental pancreatitis when administered either intravenously or as a food supplement. Methods: We designed a randomized, double-blind, placebo-controlled phase III study to test whether the administration of intravenous magnesium sulphate before and after ERCP reduces the incidence and the severity of post-ERCP pancreatitis. A total of 502 adult patients with a medical indication for ERCP are to be randomized to receive either 4930 mg magnesium sulphate (= 20 mmol magnesium) or placebo 60 min before and 6 hours after ERCP. The incidence of clinical post-ERCP pancreatitis, hyperlipasemia, pain levels, use of analgetics and length of hospital stay will be evaluated. Conclusions: If magnesium sulphate is found to be effective in preventing post-ERCP pancreatitis, this inexpensive agent with limited adverse effects could be used as a routine pharmacological prophylaxis.Trial registration: Current Controlled Trials ISRCTN46556454.

AB - Background: Acute pancreatitis is the most common complication of diagnostic and therapeutic endoscopic retrograde cholangiopancreatography (ERCP). In spite of continuing research, no pharmacologic agent capable of effectively reducing the incidence of ERCP-induced pancreatitis has found its way into clinical practise. A number of experimental studies suggest that intrapancreatic calcium concentrations play an important role in the initiation of intracellular protease activation, an initiating step in the course of acute pancreatitis. Magnesium can act as a calcium-antagonist and counteracts effects in calcium signalling. It can thereby attenuate the intracellular activation of proteolytic digestive enzymes in the pancreas and reduces the severity of experimental pancreatitis when administered either intravenously or as a food supplement. Methods: We designed a randomized, double-blind, placebo-controlled phase III study to test whether the administration of intravenous magnesium sulphate before and after ERCP reduces the incidence and the severity of post-ERCP pancreatitis. A total of 502 adult patients with a medical indication for ERCP are to be randomized to receive either 4930 mg magnesium sulphate (= 20 mmol magnesium) or placebo 60 min before and 6 hours after ERCP. The incidence of clinical post-ERCP pancreatitis, hyperlipasemia, pain levels, use of analgetics and length of hospital stay will be evaluated. Conclusions: If magnesium sulphate is found to be effective in preventing post-ERCP pancreatitis, this inexpensive agent with limited adverse effects could be used as a routine pharmacological prophylaxis.Trial registration: Current Controlled Trials ISRCTN46556454.

UR - http://www.scopus.com/inward/record.url?scp=84872138865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872138865&partnerID=8YFLogxK

U2 - 10.1186/1471-230X-13-11

DO - 10.1186/1471-230X-13-11

M3 - Article

SP - 11

JO - BMC Gastroenterology

JF - BMC Gastroenterology

SN - 1471-230X

ER -